Neuroinflammation In Parkinson'S Disease represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Pathological alpha-synuclein aggregates act as Damage-Associated Molecular Patterns (DAMPs) that activate innate immune responses: [1]
| Phenotype | Markers | Secreted Factors | Function | [2]
|-----------|---------|------------------|----------| [3]
| M1 (Classical) | CD16, CD32, CD86, iNOS | TNF-α, IL-1β, IL-6, ROS | Pro-inflammatory, cytotoxic | [4]
| M2 (Alternative) | CD206, Arg1, YM1, Fizz1 | IL-4, IL-10, BDNF, IGF-1 | Anti-inflammatory, neuroprotective | [5]
In PD, microglia predominantly adopt the M1 phenotype, contributing to chronic neuroinflammation [2]. [6]
| Cytokine | Source | Effect in PD | Therapeutic Target | [7]
|----------|--------|--------------|-------------------| [8]
| TNF-α | Microglia, astrocytes | Neuronal apoptosis, BBB disruption | Etanercept, Infliximab | [9]
| IL-1β | Microglia | Promotes alpha-syn aggregation | Anakinra, Canakinumab | [10]
| IL-6 | Microglia, astrocytes | Neurotoxicity, gliosis | Tocilizumab | [11]
| IFN-γ | T cells, NK cells | Microglial priming | Anti-IFN-γ antibodies | [5:1]
| Chemokine | Receptor | Role in PD | [6:1]
|-----------|----------|------------|
| CXCL12 (SDF-1) | CXCR4 | Microglial recruitment |
| CCL2 (MCP-1) | CCR2 | Monocyte infiltration |
| CCL3 (MIP-1α) | CCR1/5 | Neuroinflammation amplification |
The NLRP3 inflammasome is a key driver of neuroinflammation in PD:
| Gene | Function | Effect on Neuroinflammation |
|---|---|---|
| LRRK2 | Kinase | Enhances microglial activation |
| GBA | Lysosomal enzyme | Impairs autophagy, increases inflammation |
| TREM2 | Microglial receptor | Alters microglial response |
| CD33 | Immune receptor | Increases inflammation |
| HLA-DRB1 | MHC class II | Antigen presentation |
LRRK2 mutations (G2019S, R1441C/G/H) enhance microglial activation:
Neuroinflammation contributes to BBB breakdown in PD:
| Target | Drug Class | Examples | Status |
|---|---|---|---|
| NLRP3 | Small molecule inhibitors | MCC950, Dapansutrile | Preclinical |
| IL-1β | IL-1 receptor antagonist | Anakinra | Phase II |
| TNF-α | Monoclonal antibodies | Etanercept | Phase II |
| COX-2 | NSAIDs | Ibuprofen, Celecobex | Observational |
| CSF1R | Receptor antagonists | PLX3397 | Phase I |
| Biomarker | Sample | Level in PD |
|---|---|---|
| TNF-α | CSF, plasma | Elevated |
| IL-1β | CSF, plasma | Elevated |
| IL-6 | CSF, plasma | Elevated |
| NfL | Plasma | Elevated |
| YKL-40 | CSF | Elevated |
| sTREM2 | CSF | Variable |
| Pathway | Interaction |
|---|---|
| Alpha-synuclein aggregation | Triggers microglial activation; spread via neuroinflammation |
| Mitochondrial dysfunction | Source of ROS; activates NLRP3 |
| GBA/lysosomal pathway | Impairs autophagy; increases inflammatory burden |
| Oxidative stress | Amplifies inflammatory response |
| Excitotoxicity | synergizes with inflammation |
The traditional M1/M2 classification of microglia is an oversimplification. Modern single-cell studies have revealed substantial microglial heterogeneity in PD, with distinct populations emerging in different disease stages and brain regions [7:1].
Disease-associated microglia represent a spectrum of activation states:
The Human Microglia Atlas (HuMicA) has identified disease-specific microglial subsets that may serve as therapeutic targets [8:1].
Microglial responses vary across brain regions:
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) variants are associated with increased PD risk, highlighting the importance of microglial phagocytosis in disease pathogenesis [9:1].
TREM2 activates through interaction with ligands including:
Certain TREM2 variants increase PD risk by:
TREM2-targeting strategies include:
While microglia dominate the neuroinflammatory conversation, astrocytes play crucial supporting roles [12].
Astrocytes undergo characteristic changes in PD:
Astrocytes contribute to neuroinflammation through:
Emerging approaches include:
PD pathogenesis involves bidirectional communication between the gut and brain, with neuroinflammation as a key mediator [11:1].
Peripheral inflammatory signals reach the brain through:
Evidence supports the gut-brain connection:
Beyond the CNS, systemic inflammation drives PD progression [13]:
Systemic inflammation provides:
| Biomarker | Sample | Level in PD |
|---|---|---|
| TNF-α | CSF, plasma | Elevated |
| IL-1β | CSF, plasma | Elevated |
| IL-6 | CSF, plasma | Elevated |
| NfL | Plasma | Elevated |
| YKL-40 | CSF | Elevated |
| sTREM2 | CSF | Variable |
Emerging biomarkers include:
Recent publications highlighting key advances in this mechanism:
Jo MG, Kim SH, Yun SP. Hidden face of Parkinson's disease: Is it a new autoimmune disease?. Neural Regen Res. 2026. ↩︎
Jahan I, Harun-Ur-Rashid M, Islam MA. Neuronal plasticity and its role in Alzheimer's disease and Parkinson's disease. Neural Regen Res. 2026. ↩︎
She K, Yuan N, Huang M. Emerging role of microglia in the developing dopaminergic system: Perturbation by early life stress. Neural Regen Res. 2026. ↩︎
Wang Y, Li D, Xu K. Copper homeostasis and neurodegenerative diseases. Neural Regen Res. 2025. ↩︎
Bhang MK et al. Microglial heterogeneity in Parkinson disease: implications for targeted therapies. 2024. ↩︎ ↩︎
Martins-Ferreira R et al. The Human Microglia Atlas (HuMicA) unravels changes in disease-associated microglia subsets. Nat Commun (2025). 2025. ↩︎ ↩︎
Zhang L et al. TREM2 polymorphisms and Parkinson disease risk. 2024. ↩︎ ↩︎
Tansey MG et al. (2022). 2022. ↩︎
Li Y et al. Gut-brain axis in Parkinson disease: neuroinflammation links. 2024. ↩︎ ↩︎
Chen Q et al. Astrocyte reactivity in Parkinson disease: from mechanisms to therapeutic targets. 2024. ↩︎
Smith A et al. Peripheral inflammation and PD progression: a meta-analysis. 2024. ↩︎